Background: Many sero-epidemiological and case-control studies suggest that H. pylori infection may be associated with the development of lung cancer.
Aim: The objective of this study was to investigate the relation between lung cancer and Helicobacter pylori infection.
Methods: 66 consecutive patients with histologically confirmed, primary lung cancer and 66 controls were enrolled in this study. All enrolled subject underwent an enzyme-linked immunosorbent assay (ELISA) IgG serologic test for H. pylori diagnosis.
Results: The study included 66 histologically verified lung carcinoma (53 men and 13 women) with the median age of 59 years (range 30 to 87 years) and 66 controls (50 men and 16 women) with the median age of 58 years (range 27 to 88 years). The prevalence of H. pylori seropositivity was 73% (48/66) in lung cancer but only 51% (34/66) in controls. The odds ratio for the association of H. pylori and lung cancer was 2.51 (95% CI 1.14-5.54, P < 0.05).
Conclusion: The results of our study show that the population of patients with lung cancer has a significantly higher rate of seropositivity for antibodies against H.pylori than the population of subjects without lung cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Treating Tobacco Use Within Lung Cancer Screening Programs Is Optimal.
JAMA Intern Med
January 2025
Stanford Prevention Research Center, Department of Medicine, School of Medicine, Stanford University, Palo Alto, California.
Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Randomized Clinical Trial.
JAMA Intern Med
January 2025
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
Importance: The optimal configuration of a smoking cessation intervention in a lung cancer screening (LCS) setting has not yet been established.
Objective: To evaluate the efficacy of 3 tobacco treatment strategies of increasing integration and intensity in the LCS setting.
Design, Setting, And Participants: In this randomized clinical trial, LCS-eligible current smokers were randomized into 3 treatments: quitline (QL), QL plus (QL+), or integrated care (IC).
Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China.
Int J Clin Pharm
January 2025
Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing, 100191, China.
Background: Lung cancer is the leading cause of cancer-related deaths in China, and pembrolizumab shows differential efficacy in advanced non-small cell lung cancer (NSCLC) with different PD-L1 expression levels.
Aim: To assess the cost-effectiveness of PD-L1 testing associated with pembrolizumab for first-line treatment of NSCLC from the perspective of Chinese healthcare system.
Method: Over a lifetime horizon, a three-state partitioned survival model was developed to assess the cost-effectiveness of PD-L1 testing and no PD-L1 testing.
Cytologic diagnosis of fumarate hydratase-deficient renal cell carcinoma: A single-institutional experience.
Cancer Cytopathol
February 2025
Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Background: Fumarate hydratase-deficient renal cell carcinoma (FHRCC) is an aggressive carcinoma that typically presents as advanced-stage disease. Prompt recognition of FHRCC is critical for appropriate clinical care and genetic counseling for patients and family members. However, diagnosing FHRCC from cytology specimens is challenging, with limited characterization and no reports describing prospectively identified cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!